Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Capital Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Capital Leases fell 34.32% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 34.32% year-over-year, with the annual reading at $1.5 million for FY2025, 34.32% down from the prior year.
  • Capital Leases for Q4 2025 was $1.5 million at Kymera Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Capital Leases was $2.2 million in Q4 2024, with the low at $498000.0 in Q1 2021.
  • Average Capital Leases over 5 years is $1.3 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Capital Leases plummeted 48.78% in 2022, then skyrocketed 171.23% in 2024.
  • Over 5 years, Capital Leases stood at $1.1 million in 2021, then increased by 9.3% to $1.2 million in 2022, then grew by 4.41% to $1.3 million in 2023, then soared by 71.1% to $2.2 million in 2024, then tumbled by 34.32% to $1.5 million in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $1.5 million, $1.8 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.